Nest-1 is under clinical development by Nested Therapeutics and currently in Phase I for Non-Small Cell Lung Cancer. According to GlobalData, Phase I drugs for Non-Small Cell Lung Cancer have an 80% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Nest-1’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Nest-1 overview
NST-628 is under development for the treatment of solid tumor, non-small lung cancer, central nervous system (CNS) tumor like glioma and melanoma. The drug candidate is a non-degrading, molecular glue that acts by targeting RAS/MAPK pathway. It is administered through oral route.
Nested Therapeutics overview
Nested Therapeutics (Nested) is a biotechnology company. It discovers and develops novel small-molecule precision medicine therapies for cancer treatment by using mutation clusters to identify druggable pockets. The company’s lead product candidate, NEST-1, a non-degrading molecule glue that targets multiple critical components in the RAS/MAPK pathway. Nested’s pipeline also includes NEST-2, NEST-3, NEST-4, and NEST-5 drug candidates. The company utilizes its proprietary insightful drug discovery platform that maps mutational clusters onto structural proteome, designs drugs optimized for druggable pocket, and identifies druggable-pocket and cancer-driving mechanisms. Nested is headquartered in Cambridge, Massachusetts, the US.
For a complete picture of Nest-1’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.